Fingerprint
Dive into the research topics of 'Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Naveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, Claire Harrison, Rami S Komrokji, Andrew Perkins, Rosa M Ayala Diaz, David Lavie, Akihiro Tomita, Yang Feng, Qin Qin, Jason Harb, Akshanth R Polepally, Jalaja Potluri, Jacqueline S Garcia
- University of Texas MD Anderson Cancer Center
- Department of Haematology
- Malignant Hematology Department
- Moffitt Cancer Center
- Monash University
- Complutense University
- Hadassah-Hebrew University Medical Center
- Fujita Health University School of Medicine
- Clinical Development Oncology
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review